Negative feedback of SNRK to circ-SNRK regulates cardiac function post-myocardial infarction

Zhi-Yan Wang1, Xiao-Xiao Liu2, Yun-Fei Deng3

  • 1Department of cardiovascular medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Insights

A novel circular RNA, circ-SNRK, enhances cardiac mitochondrial efficiency by regulating the miR-33/SNRK axis. This circRNA shows therapeutic potential for heart failure by improving cardiac function post-myocardial infarction.

Area of Science:

  • Cardiovascular Biology
  • Molecular Cardiology
  • RNA Biology

Background:

  • Myocardial infarction (MI) impairs cardiac function, often leading to heart failure due to reduced oxygen and substrate delivery.
  • Cardiac mitochondrial efficiency is crucial for maintaining heart function and energy metabolism.

Purpose of the Study:

  • To identify novel regulatory mechanisms of cardiac energy metabolism in response to ischemia.
  • To investigate the role of circular RNAs in the pathophysiology of heart failure post-MI.

Main Methods:

  • Identification and characterization of circ-SNRK in cardiomyocytes (CMs).
  • Investigation of the circ-SNRK interaction with miR-33 and SNRK (sucrose nonfermenting 1-related kinase).
  • Analysis of NOVA1 (NOVA alternative splicing regulator 1) involvement in circ-SNRK formation.
  • In vivo studies using rat models of myocardial infarction.

Main Results:

  • Circ-SNRK sponges miR-33, enhancing ATP synthesis via SNRK, establishing a circ-SNRK-miR-33-SNRK axis.
  • A negative feedback loop involving SNRK cleavage, nuclear entry, and NOVA1 binding inhibits circ-SNRK formation.
  • Overexpression of exogenous circ-SNRK improved cardiac function in rats post-MI, breaking the inhibitory loop.

Conclusions:

  • The circ-SNRK/SNRK negative feedback loop regulates cardiomyocyte (CM) energy metabolism.
  • Circ-SNRK represents a potential therapeutic target for heart failure by modulating cardiac energy metabolism.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
574
Pathophysiology of Cardiac Performance01:29

Pathophysiology of Cardiac Performance

Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
894
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
103
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.0K